Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
18F-FDG PET/CT
Immunotherapy, Adoptive
Lugano criteria
Lymphoma
Receptors, Chimeric antigen
Tumor growth rate
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
28
06
2023
accepted:
10
10
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
aheadofprint
Résumé
Chimeric antigen receptor T-cell therapy (CART) can be administered outpatient yet requires management of potential side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The pre-infusion tumor burden is associated with CRS, yet there is no data on the relevance of pre-infusion tumor growth rate (TGR). Our objective was to investigate TGR for the occurrence and severity of CRS and ICANS. Consecutive patients with available pre-baseline and baseline (BL) imaging before CART were included. TGR was determined as both absolute (abs) and percentage change (%) of Lugano criteria-based tumor burden in relation to days between exams. CRS and ICANS were graded according to ASTCT consensus criteria. Clinical metadata was collected including the international prognostic index (IPI), patient age, ECOG performance status, and LDH. Sixty-two patients were included (median age: 62 years, 40% female). The median pre-BL TGR [abs] and pre-BL TGR [%] was 7.5 mm
Identifiants
pubmed: 37861736
doi: 10.1007/s00277-023-05507-9
pii: 10.1007/s00277-023-05507-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Faculty LMU, "FöFoLe"
ID : 1147
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379:64–73. https://doi.org/10.1056/NEJMra1706169
doi: 10.1056/NEJMra1706169
pubmed: 29972754
pmcid: 7433347
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45–56. https://doi.org/10.1056/NEJMoa1804980
doi: 10.1056/NEJMoa1804980
pubmed: 30501490
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545–2554. https://doi.org/10.1056/NEJMoa1708566
doi: 10.1056/NEJMoa1708566
pubmed: 29226764
pmcid: 5788566
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531–2544. https://doi.org/10.1056/NEJMoa1707447
doi: 10.1056/NEJMoa1707447
pubmed: 29226797
pmcid: 5882485
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382:1331–1342. https://doi.org/10.1056/NEJMoa1914347
doi: 10.1056/NEJMoa1914347
pubmed: 32242358
pmcid: 7731441
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https://doi.org/10.1186/s40425-018-0343-9
doi: 10.1186/s40425-018-0343-9
pubmed: 29907163
pmcid: 6003181
Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, Lopez JA, Chen J, Chung D, Harju-Baker S et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295–2306. https://doi.org/10.1182/blood-2017-06-793141
doi: 10.1182/blood-2017-06-793141
pubmed: 28924019
pmcid: 5701525
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
doi: 10.1016/j.bbmt.2018.12.758
pubmed: 30592986
Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE et al (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5:2799–2806. https://doi.org/10.1182/bloodadvances.2021004575
doi: 10.1182/bloodadvances.2021004575
pubmed: 34264268
pmcid: 8341350
Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, Batlevi C, Brentjens RJ, Dahi PB, Devlin SM et al (2021) Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv 5:3397–3406. https://doi.org/10.1182/bloodadvances.2020003885
doi: 10.1182/bloodadvances.2020003885
pubmed: 34432870
pmcid: 8525234
Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ et al (2020) Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4:5414–5424. https://doi.org/10.1182/bloodadvances.2020003092
doi: 10.1182/bloodadvances.2020003092
pubmed: 33147337
pmcid: 7656920
Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV et al (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133:2212–2221. https://doi.org/10.1182/blood-2018-12-893396
doi: 10.1182/blood-2018-12-893396
pubmed: 30808634
Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958–971. https://doi.org/10.1158/2159-8290.CD-17-1319
doi: 10.1158/2159-8290.CD-17-1319
pubmed: 29880584
pmcid: 6385599
Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85–96. https://doi.org/10.1038/s41577-021-00547-6
doi: 10.1038/s41577-021-00547-6
pubmed: 34002066
Bansal R, Paludo J, Hathcock MA, Spychalla MT, Khurana A, Hampel PJ, Durani U, Alkhateeb HB, Dingli D, Hayman SR et al (2022) Outpatient practice pattern for recently approved CAR-T in patients with lymphoma and multiple myeloma. Blood 140:2399–2401. https://doi.org/10.1182/blood-2022-167187
doi: 10.1182/blood-2022-167187
Borogovac A, Keruakous A, Bycko M, HolterChakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT et al (2022) Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant 57:1025–1027. https://doi.org/10.1038/s41409-022-01664-z
doi: 10.1038/s41409-022-01664-z
pubmed: 35411106
pmcid: 8995917
Meignan M, Cottereau AS, Specht L, Mikhaeel NG (2021) Total tumor burden in lymphoma - an evolving strong prognostic parameter. Br J Radiol 94:20210448. https://doi.org/10.1259/bjr.20210448
doi: 10.1259/bjr.20210448
pubmed: 34379496
pmcid: 8553180
Gobbi PG (2014) Tumor burden in Hodgkin’s lymphoma: much more than the best prognostic factor. Crit Rev Oncol Hematol 90:17–23. https://doi.org/10.1016/j.critrevonc.2013.11.002
doi: 10.1016/j.critrevonc.2013.11.002
pubmed: 24290380
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferte C, Massard C, Soria JC (2011) Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 47:2512–2516. https://doi.org/10.1016/j.ejca.2011.06.012
doi: 10.1016/j.ejca.2011.06.012
pubmed: 21763126
Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C et al (2014) Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res : An Off J Am Assoc Cancer Res 20:246–252. https://doi.org/10.1158/1078-0432.CCR-13-2098
doi: 10.1158/1078-0432.CCR-13-2098
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bucklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P et al (2023) Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. Cytotherapy. https://doi.org/10.1016/j.jcyt.2023.03.007
doi: 10.1016/j.jcyt.2023.03.007
pubmed: 37055322
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068. https://doi.org/10.1200/JCO.2013.54.8800
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994. https://doi.org/10.1056/NEJM199309303291402
doi: 10.1056/NEJM199309303291402
Dos Santos DMC, Rejeski K, Winkelmann M, Liu L, Trinkner P, Gunther S, Bucklein VL, Blumenberg V, Schmidt C, Kunz WG et al (2022) Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies. Haematologica. https://doi.org/10.3324/haematol.2021.280189
doi: 10.3324/haematol.2021.280189
pubmed: 35172565
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D’Aveni-Piney M, Oberic L, Bodet-Milin C, Bories P, Olivier P et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 4:5607–5615. https://doi.org/10.1182/bloodadvances.2020003001
doi: 10.1182/bloodadvances.2020003001
pubmed: 33180899
pmcid: 7686887
Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z et al (2019) Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. Biol Blood Marrow Transplant 25:1092–1098. https://doi.org/10.1016/j.bbmt.2019.02.008
doi: 10.1016/j.bbmt.2019.02.008
pubmed: 30769193
Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML et al (2020) High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4:3268–3276. https://doi.org/10.1182/bloodadvances.2020001900
doi: 10.1182/bloodadvances.2020001900
pubmed: 32702097
pmcid: 7391155
Iacoboni G, Simo M, Villacampa G, Catala E, Carpio C, Diaz-Lagares C, Vidal-Jordana A, Bobillo S, Marin-Niebla A, Perez A et al (2021) Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Ann Hematol 100:2303–2310. https://doi.org/10.1007/s00277-021-04560-6
doi: 10.1007/s00277-021-04560-6
pubmed: 34236497
Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, Soond SM, Piacentini M, Melino G, Zaritskey A et al (2018) The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis 9:897. https://doi.org/10.1038/s41419-018-0918-x
doi: 10.1038/s41419-018-0918-x
pubmed: 30181581
pmcid: 6123453
Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferte C (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748–762. https://doi.org/10.1038/s41571-018-0111-2
doi: 10.1038/s41571-018-0111-2
pubmed: 30361681
Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res : An Off J Am Assoc Cancer Res 23:1920–1928. https://doi.org/10.1158/1078-0432.CCR-16-1741
doi: 10.1158/1078-0432.CCR-16-1741
Wagner NB, Lenders MM, Kuhl K, Reinhardt L, Andre F, Dudda M, Ring N, Ebel C, Stager R, Zellweger C et al (2021) Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 9(5):e002350. https://doi.org/10.1136/jitc-2021-002350
Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C et al (2022) The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer 10(5):e004475. https://doi.org/10.1136/jitc-2021-004475
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frolich L, Ackermann J, Bucklein V et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138:2499–2513. https://doi.org/10.1182/blood.2020010543
doi: 10.1182/blood.2020010543
pubmed: 34166502
pmcid: 8893508